Medifast director trust sells 19,089 shares. Medifast stock gains 1.67 percent
A trust linked to Medifast director Daniel R. Chard sold 19,089 common shares of Medifast (MED) in late September 2026, executed under a Rule 10b5-1 trading plan. This insider sale occurred as Medifast's stock gained 1.67 percent, trading at EUR 10.34, despite the company reporting a 27.60 percent year-over-year decline in second-quarter 2026 revenue, which still exceeded analyst expectations.
Have Medifast Insiders Been Selling Stock?
This article examines recent insider trading activity at Medifast, focusing on whether insiders have been selling their stock. It implies a detailed look into transactions by company executives and directors to determine any trends or significant movements in their holdings.
Don't Ignore The Insider Selling In Medifast
A recent insider sale at Medifast (NYSE:MED) saw Non-Executive Chairman Daniel Chard divest US$226k worth of shares, representing 8.7% of his total holding. While this was the largest insider sale in the past year, the company also saw more insider buying than selling over the same period. Insiders collectively own 3.8% of Medifast stock, valued at US$4.5 million.
Q2 Earnings Roundup: Medifast (NYSE:MED) And The Rest Of The Personal Care Segment
This article provides a Q2 earnings roundup for the personal care industry, highlighting the performance of several key companies. Medifast (MED) reported a strong quarter with revenues exceeding expectations and increased EPS guidance, while e.l.f. Beauty (ELF) stood out with significant revenue growth and analyst estimate beats. Conversely, Nature's Sunshine (NATR) experienced a disappointing quarter with misses on revenue, EBITDA, and EPS estimates.
Medifast director Daniel Chard sells $226,288 in company shares
Medifast director Daniel R. Chard sold a total of $226,288 worth of company common stock in two separate transactions in late September 2026. The sales involved 9,545 shares at a weighted-average price of $11.9788 and an additional 9,544 shares at $11.73. Despite the insider sales and a revenue decline, InvestingPro analysis suggests the stock is undervalued with significant upside potential.
Medifast (NYSE:MED) Stock: Insider Daniel Chard Sells 9,544 Shares
Medifast Director Daniel Chard sold 9,544 shares of the company's stock for $11.73 per share, totaling $111,951.12, reducing his holdings by 6.81%. The transaction was part of a pre-arranged Rule 10b5-1 trading plan. Despite recent analyst downgrades to "Reduce" and a negative P/E ratio, the company's latest quarterly earnings beat analyst expectations, and institutional investors hold a significant 95.51% stake.
Medifast (NYSE:MED) Stock: Insider Daniel Chard Sells 9,545 Shares
Medifast (NYSE:MED) Director Daniel Chard sold 9,545 shares of the company's stock for a total of $114,349.10, reducing his direct ownership by 6.38%. The transaction was part of a pre-arranged Rule 10b5-1 trading plan. Medifast shares recently traded at $11.53, with a market capitalization of $128.85 million, and analysts currently rate the stock as "Reduce" with an average price target of $12.00.
A preset trading plan covers Medifast (MED) director Chard's trust sales of 9,545 and 9,544 shares.
Medifast director Daniel R. Chard's irrevocable trust sold 9,545 common shares on September 28, 2026, at a weighted-average price of $11.9788, and 9,544 shares on September 29, 2026, at a weighted-average price of $11.7300. These transactions were executed under a Rule 10b5-1 plan, and Chard is the settlor and investment trustee of the selling trust. After these sales, Chard's holdings include 130,609.352 indirect shares through the trust, 17,678 indirect shares in a joint account, and 188,233 direct shares.
Form 4 Medifast Inc For: 30 September By Investing.com
This article announces the filing of Form 4 for Medifast Inc. for the period ending September 30. It is a brief, one-sentence news item published by Investing.com, providing basic information about a company's regulatory filing. The article does not contain any further details or analysis of the filing.
Medifast (MED) officer Daniel Chard proposes selling 9,544 shares after a sale of 9,545 shares
Medifast (MED) officer Daniel Chard has proposed selling 9,544 common shares with an aggregate market value of $111,951.15 on September 29, 2026, from the Daniel and Allyson Chard FAM IRRVOC TR. This proposed sale follows a previous sale of 9,545 shares on September 28, 2026, valued at $114,337.80. The filings are made under Rule 144, which outlines conditions for reselling restricted securities.
Four stock-award lots make up Medifast (MED) officer Daniel Chard’s planned sale of 9,545 shares.
Medifast officer Daniel R. Chard plans to sell 9,545 common shares, valued at approximately $114,337.80, with an approximate sale date of September 28, 2026. The shares originate from four stock-award lots acquired between October 2018 and December 2021 and are held by the Daniel and Allyson Chard FAM IRRVOC TR. This planned sale is detailed in a Form 144 SEC filing.
Medifast, Inc. (MED) Latest Stock News & Headlines
This article provides the latest stock news and headlines for Medifast, Inc. (MED), showing its current stock price, recent performance, and related news articles. It also includes performance metrics against the S&P 500 benchmark. The information indicates a slight dip in MED's stock price at close on September 24 and highlights various news items concerning the company and its peers.
Medifast (NYSE:MED) Stock Price Passes Above Two Hundred Day Moving Average - Here's Why
Medifast (NYSE:MED) shares recently climbed above their 200-day moving average, reaching $12.48 before closing at $12.15, compared to an average of $11.28. Despite this technical performance, analyst sentiment remains cautious with a "Reduce" consensus rating and a $12.00 price target. The company recently exceeded quarterly earnings expectations, reporting a loss of $0.28 per share against an anticipated $0.65 loss, and revenue of $76.38 million.
Medifast stock gains as revenue reaches USD 76.38 million
Medifast stock saw a 20.5 percent rise after its latest report, despite a 27.6 percent year-over-year decline in revenue, which still managed to exceed analysts' expectations by 5.1 percent. The market's positive reaction is attributed to the company's above-expectation EPS guidance for the next quarter, signaling that investors are prioritizing future earnings outlook over current top-line performance. The stock traded at USD 11.73 on September 21, 2026, and its future performance will depend on whether the strong EPS guidance can counteract the revenue decline.
Medifast stock holds near 52-week low as revenue outlook weakens
Medifast Inc. (MED) stock closed at USD 11.79 on September 18, 2026, near its 52-week low, with its market capitalization at about USD 131.6 million. Analysts expect a 27.3% revenue decline for the current fiscal year. The stock's price-to-book ratio is 0.65, and the consensus price target of USD 12.00 suggests limited near-term recovery.
Medifast (NYSE:MED) Stock Price Crosses Above 200 Day Moving Average - Here's What Happened
Medifast (NYSE:MED) stock recently crossed above its 200-day moving average, reaching $12.20, although analysts maintain a "Reduce" consensus rating with a $12.00 target price. The company reported better-than-expected quarterly earnings but continues to face negative margins and has issued negative EPS guidance. Despite this, insider buying has increased, with substantial purchases by a director and other insiders in the past three months.
Medifast (NYSE:MED) Stock Crosses Above 200 Day Moving Average - Time to Sell?
Medifast (NYSE:MED) stock recently crossed above its 200-day moving average, trading at $12.6250 with a 200-day average of $11.15. Despite this technical indicator, analysts maintain a "Reduce" consensus rating with an average price target of $12.00, due to the company's unprofitability and negative earnings expectations for fiscal 2026. However, recent quarterly results exceeded revenue and EPS estimates, and insiders have purchased a significant number of shares.
Medifast (MED) Down 5.1% Since Last Earnings Report: Can It Rebound?
Medifast (MED) shares have dropped 5.1% since its last earnings report, underperforming the S&P 500. The company reported a narrower-than-expected Q1 2026 loss but a significant year-over-year revenue decline due to fewer active OPTAVIA coaches, although coach productivity improved. Medifast faces continued challenges from GLP-1 weight-loss medications and projects continued losses for 2026, with anticipated profitability improvements starting in Q4 2026.
Why Is Medifast (MED) Down 7.6% Since Last Earnings Report?
Medifast (MED) shares have dropped 7.6% since its last earnings report, underperforming the S&P 500 despite narrower-than-expected Q2 2026 losses and improved coach productivity. The company's revenue declined due to a smaller coach network and broader industry pressures like GLP-1 weight-loss medications, but management expects a return to profitability in Q4 2026 and beyond. Medifast has a Zacks Rank #2 (Buy), with estimates trending upward.
Medifast (NYSE:MED) Director Purchases 43,150 Shares
Medifast Director Parsa Kiai recently purchased 43,150 shares of Medifast stock for $529,019, increasing his direct ownership by 6.5%. This transaction follows three other purchases made in August, bringing his total recent buying activity to over 120,000 shares. Despite the insider buying and better-than-expected quarterly revenue, analysts maintain a "Reduce" rating for Medifast with a target price of $12.00.
Medifast® Announces the Launch of the Medifast Metabolic Health Institute™
Medifast, Inc. has launched the Medifast Metabolic Health Institute to advance metabolic health through rigorous research, evidence-based education, and clinical expertise. This initiative solidifies Medifast's focus on metabolic health, following the introduction of its new consumer brand, Trilivy™. The institute leverages Medifast's 45 years of clinical research and is guided by expert fellows and an advisory board to translate scientific discoveries into practical applications and support for individuals seeking optimal metabolic health.
Parsa Kiai Buys 4,329 Shares of Medifast (NYSE:MED) Stock
Medifast Director Parsa Kiai recently purchased 4,329 shares of the company's stock for $12.00 per share, totaling $51,948. This transaction increased his holdings to 665,517 shares. Despite exceeding analysts' quarterly revenue and EPS estimates, Medifast continues to face a "Reduce" consensus rating from analysts, with expected losses through fiscal 2028, though earnings forecasts have shown improvement.
Can Medifast Capitalize on Rising GLP-1 Use With Metabolic Health?
Medifast (MED) is transitioning strategically towards metabolic health with its new 3.0 strategy, including the launch of the consumer brand Trilivy and the Medifast Metabolic Health Institute. The company aims to broaden its offerings for coaches and clients, addressing the needs of those on GLP-1 medications, transitioning off them, or seeking non-drug pathways, particularly focusing on targeted fat loss and lean mass preservation. This shift is expected to open new growth avenues, supported by positive trends and a strong Zacks Rank #2 (Buy) recommendation despite a projected decline in current fiscal year earnings.
Medifast (NYSE: MED) director adds 43K shares in open-market buy
Medifast director Parsa Kiai indirectly purchased 43,150 shares of MED common stock on August 26, 2026, through Steamboat Capital funds. The shares were bought in two open-market transactions at an average price of $12.2632 per share, totaling approximately $529,000. Kiai disclaims beneficial ownership except for his pecuniary interest, and the transactions were not made under a Rule 10b5-1 plan.
MED | Medifast, Inc. Financials - Revenue Breakdown
This article provides a financial overview of Medifast, Inc. (MED), focusing on its revenue breakdown. It details congressional trading activity involving MED, insider trading data, institutional holdings, and key financial statements, but notes the absence of specific segment or geographical revenue data. The company is described as a health and wellness firm known for its OPTAVIA program, addressing obesity and promoting a healthy lifestyle.
Medifast director Parsa Kiai acquires $842,698 in company shares By Investing.com
Medifast director Parsa Kiai recently acquired shares in the company totaling $842,698 through indirect transactions on August 19 and August 20, 2026. The stock is currently trading at $11.95, and InvestingPro analysis suggests it may be undervalued despite the company not being profitable over the last twelve months. This comes after Medifast reported better-than-expected Q2 2026 financial results, with a smaller loss per share and higher revenue than anticipated.
Medifast director Parsa Kiai acquires $842,698 in company shares
Medifast director Parsa Kiai recently acquired $842,698 worth of company shares through indirect transactions on August 19 and August 20, 2026. The shares were purchased via Steamboat Capital Partners Master Fund, LP and Steamboat Capital Partners II, LP, where Kiai serves as Managing Member. Despite impressive gross profit margins, Medifast has not been profitable over the last twelve months, though it recently surpassed Q2 2026 financial expectations.
Medifast Inc (MDF) Q4 2025 Earnings Report - Results, Call & Slides
Medifast (MDF) reported its Q4 2025 earnings, beating analyst expectations for both EPS and revenue. The company posted an actual EPS of -€0.48 against a consensus of -€0.71, and actual revenue of €64.95M compared to an expected €61.76M. Medifast's next earnings report is estimated for November 9, 2026.
Medifast (NYSE: MED) sees Steamboat Capital build 790,693-share stake
Steamboat Capital Partners, LLC and its managing member, Parsa Kiai, have reported a 7.1% ownership stake in Medifast (NYSE: MED), beneficially owning 790,693 shares of common stock. This stake, acquired for approximately $8.36 million, was funded through open-market purchases using client working capital, potentially including margin loans. Recent significant purchases include shares bought on August 19 and August 20, 2026.
Insider Buying: Medifast (NYSE:MED) Director Acquires 29,337 Shares of Stock
Medifast Director Parsa Kiai recently acquired a total of 72,487 shares of the company's stock across two transactions, investing over $842,000. These purchases increased his direct stake to 619,331 shares. Despite the insider buying, Medifast's stock has a "Reduce" consensus rating with a $12.00 price target, and institutional investors own a significant 95.51% of outstanding shares.
Medifast (NYSE:MED) Director Purchases 43,150 Shares of Stock
Medifast Director Parsa Kiai recently purchased 43,150 shares of the company's stock for $500,540, increasing his direct ownership by almost 7%. This follows a previous purchase of 29,337 shares the day before. Despite the insider buying and recent earnings beat, analysts maintain a "Reduce" rating with a $12.00 target price for Medifast (NYSE: MED).
Medifast director Parsa Kiai acquires $842,698 in company shares
Medifast director Parsa Kiai recently acquired $842,698 worth of company shares through indirect transactions on August 19 and 20, 2026. The shares were purchased at average prices between $11.6037 and $11.6576. Despite impressive gross profit margins, the company has not been profitable over the last twelve months, though it recently surpassed Q2 2026 financial expectations.
Medifast director Parsa Kiai acquires $842,698 in company shares By Investing.com
Medifast director Parsa Kiai indirectly acquired shares worth $842,698 on August 19 and 20, 2026, through investment entities he manages. The acquisitions occurred at average prices between $11.6037 and $11.6576 per share, with the company's stock currently trading at $11.95. Despite Medifast's impressive gross profit margins, it has not been profitable over the last twelve months, although it recently surpassed analyst expectations for Q2 2026 financial results.
Medifast (NYSE: MED) director buying near $11 — see how many shares he added
Medifast (NYSE: MED) director Parsa Kiai indirectly purchased a total of 72,487 shares of common stock on August 19-20, 2026. These transactions were made through Steamboat Capital funds at weighted-average prices around $11.60 and $11.66 per share. Kiai disclaims full beneficial ownership, asserting a pecuniary interest in the shares, and the purchases were not made under a Rule 10b5-1 trading plan.
Can Medifast's New Compensation Plan Accelerate Coach Growth?
Medifast has introduced an enhanced compensation plan aimed at strengthening its network of Executive Directors, which is seen as a key driver for business growth. Despite a significant year-over-year decline in active coaches, the company has seen a 41% increase in average revenue per coach, indicating improved productivity. This new plan, if successful in building a stronger Executive Director base and sustaining coach productivity, could boost coach growth and revenue for Medifast.
Can Medifast's New Compensation Plan Accelerate Coach Growth?
Medifast has introduced an enhanced compensation plan to strengthen its network of Executive Directors, who are seen as the primary drivers of sustainable business growth. This initiative follows a significant decline in active earning coaches due to GLP-1 medication adoption, though average revenue per coach has increased. The company hopes this new plan, by fostering stronger leadership and improving coach productivity, will lead to future coach and revenue growth.
MEDIFAST INC Dividend | MED Dividend History & Yield
This article provides detailed dividend information for MEDIFAST INC (MED), including historical dividend distributions, current yield, and key financial metrics. It shows the stock's performance, market capitalization, P/E ratio, and upcoming earnings date. The content emphasizes that the data is for reference only and not investment advice.
Can Medifast's New Compensation Plan Accelerate Coach Growth?
Medifast (MED) has introduced an enhanced compensation plan aimed at boosting its network of Executive Directors, who are crucial for sustainable business growth. This new strategy seeks to improve leadership development and coach productivity, as reflected in a 41% increase in average revenue per active earning coach despite a 48.7% decline in overall coach numbers due to GLP-1 medication adoption. If successful, the plan is expected to drive coach growth and revenue for Medifast, which currently holds a Zacks Rank #3 (Hold).
Medifast (MED): Citadel entities and Kenneth Griffin disclose sub‑5% ownership stake
Citadel entities, including Citadel Securities LLC and Citadel Advisors LLC, along with Kenneth Griffin, have filed an amended Schedule 13G disclosing beneficial ownership of Medifast (MED) common stock. The filing indicates that each reporting person holds less than 5% of Medifast's outstanding shares, with Kenneth Griffin holding the largest individual stake at 2.6%. All reported ownership is based on 11,119,115 shares outstanding as of April 27, 2026, with all reporting persons having shared, rather than sole, voting and dispositive power.
Susquehanna group reports 5.3% Medifast (MED) ownership in Schedule 13G
Susquehanna Portfolio Strategies, LLC and Susquehanna Securities, LLC have collectively reported a 5.3% beneficial ownership stake in Medifast (MED) through a Schedule 13G filing. This amounts to 587,214 shares of Medifast common stock as of June 30, 2026, including options for 542,700 shares held by Susquehanna Securities, LLC. The filing indicates a passive investment purpose, and both entities maintain sole voting and dispositive power over their directly owned shares, with shared power over the total beneficially owned shares.
Medifast (NYSE:MED) Cut to Hold at Zacks Research
Zacks Research downgraded Medifast (NYSE:MED) from "strong buy" to "hold," with Weiss Ratings maintaining a "sell (e+)" rating. The stock has an average "reduce" rating and a consensus price target of $12. Medifast beat earnings and revenue expectations for the last quarter, but still posted negative margins and analysts anticipate a full-year loss.
Can Medifast's Coach Productivity Gains Help Revive Revenue Growth?
Medifast (MED) has seen its revenues stabilize due to increased coach productivity, which rose for the third consecutive quarter in Q2 fiscal 2026. This improvement, with revenue per active earning coach reaching $6,529, suggests a positive trend despite a declining number of active coaches. The company expects continued productivity gains and aims for a return to profitability by Q4 2026, supported by improved client retention and a strategic shift towards metabolic health.
Medifast (MED): Charles Schwab Investment Management reports 3.6% ownership stake
Charles Schwab Investment Management Inc. has reported a 3.6% beneficial ownership stake in Medifast Inc. This amounts to 396,996 shares of common stock, over which Charles Schwab Investment Management Inc. holds sole voting and sole dispositive power. The filing, a Schedule 13G/A, indicates a passive investment intent.
Medifast’s Q2 Earnings Call: Our Top 5 Analyst Questions
Medifast (MED) reported Q2 CY2026 results that exceeded Wall Street expectations for revenue and EPS, driven by improved coach productivity and the new Trilivy brand. The company reconfirmed its full-year revenue guidance and provided positive EPS guidance. Analysts focused on the Catalyst program's cost savings, the path to profitability, coach reception to Trilivy, and future margin trajectory during the earnings call.
Medifast’s Q2 Earnings Call: Our Top 5 Analyst Questions
Medifast's Q2 earnings surpassed analyst expectations, driven by improved coach productivity and the new Trilivy brand. The company reconfirmed its full-year revenue and EPS guidance. Analysts focused on the Catalyst program's costs and profitability impact, coach reception to Trilivy, and future margin trajectory.
Can MED's Trilivy Launch and Cost Cuts Drive a Q4 Profit Turnaround?
Medifast (MED) is launching its new Trilivy metabolic-health platform and implementing further cost reductions through its Catalyst program, aiming for a return to profitability in Q4 2026. While Q2 2026 revenues fell year-over-year, they still beat estimates, and coach productivity has shown improvement. The company faces ongoing challenges with shrinking coach numbers and projected losses before Q4, making the turnaround dependent on Trilivy's success, revenue stability, and effective cost savings.
MED Rallies 13.6% in the Past Month: Can the Momentum Keep Building?
Medifast (MED) shares have risen 13.6% in the past month, outperforming the industry, driven by narrower-than-expected Q2 2026 losses and improving coach productivity. While revenue and the active coach base remain under pressure, management expects continued productivity gains and has maintained full-year revenue guidance, suggesting potential for sustained momentum despite a mixed operational backdrop.
Is MED Worth Buying as Low Valuation Meets a High-Risk Turnaround?
Medifast (MED) presents a challenging investment scenario with a low forward sales valuation compared to its industry, but faces significant headwinds including declining revenues, a shrinking coach network, and ongoing losses. Despite these challenges, the company's strong balance sheet provides a cushion for its Trilivy-led turnaround efforts, which have shown early signs of improved coach productivity. The success of this turnaround hinges on Medifast's ability to drive client acquisition, grow its coach network, and ultimately return to profitability, with management targeting this goal by Q4 2026.
MED Rallies 13.6% in the Past Month: Can the Momentum Keep Building?
Medifast (MED) shares have rallied 13.6% in the past month, outperforming the industry's growth, driven by improving coach productivity and narrowing earnings loss. Despite this, the company still faces challenges with a shrinking coach base and mixed Style Scores, indicating that sustained momentum will depend on continued productivity gains, firmer revenues, and progress toward profitability.
MEDIFAST INC 2026: Revenue $76.38M, EPS ($0.28) — 10-Q Summary
MEDIFAST INC reported its 2026 quarterly results with a significant decline in revenue to $76.38M from $105.56M a year prior, leading to a net loss of ($3.1M) and diluted EPS of ($0.28). This decline was primarily attributed to a roughly 28% drop in active earning coaches. The company launched new initiatives like the Trilivy brand and a new coach compensation plan to improve productivity and retention.
